Novel PDE IV inhibitors: exploring their potential in asthma

Jack, Dr David B

Inpharma Weekly (1012):p 9-10, November 11, 1995.

The enzyme phosphodiesterase (PDE) IV is a target for several companies seeking to develop innovative agents with both anti-asthmatic and anti-inflammatory properties. Several novel PDE IV inhibitors, such as RP-73401 [Rhône-Poulenc Rorer], CDP-840 [Celltech] and SB-207499 [SmithKline Beecham] are now in development. The most recent findings with these compounds were presented at the Second World Congress on Inflammation [Brighton, UK; September 1995].